



The OECD Framework for AOP Development and Application

Magda Sachana

The Danish 3R-symposium: 3R-successes
13th and 14th September 2016,



Presentation Outline

- OECD AOP Development Programme
 - Background
 - OECD work on predictive toxicology
 - Main milestones
 - IT tools



Background



Use of animals for human and ecological risk assessments

Skin sensitization

Dermal toxicity

Acute toxicity



Chronic toxicity

Genotoxicity

Carcinogenicity



Eye irritation / corrosion

Skin irritation / corrosion



Reproduction toxicity

Neurotoxicity

Development toxicity




Data quality ensured by

OECD Test Guidelines


**OECD Principles of
Good Laboratory Practise and
Compliance Monitoring Procedures**

Mutual Acceptance of Data






Growing concern over lack of toxicological data





Countries are improving their legislation to assess more chemicals in a shorter time frame



CHEMICALS
MANAGEMENT
PLAN

PLAN DE
GESTION DES
PRODUITS CHIMIQUES



Standard toxicity testing is costly, time consuming and requires many animals



5000 animals / chemical



Test duration
30 – 720 days




Costs
€2,000 - €2,000,000




Promoting the use of non-animal methods

- OECD Test Guidelines based on non-animal methods (skin and eye corrosion/irritation, phototoxicity, skin absorption and sensitisation, genotoxicity)
- Development of models to predict the toxicity of chemicals (grouping of chemicals and read across)
- Computational methods






Need for mechanistic understanding




Test Chemical



Developmental & Reproductive toxicity



Identifying the mechanism(s)



 = Key Event


 = Key Event Relationship





OECD work on Predictive Toxicology



AOP's central role in OECD work on predictive toxicology



Key events can be measured with non-animal tests, which can be used to predict the adverse outcome




Molecular Organelle Cellular Tissue Organ Organism Population



Types of Information




Selection of methods for Test Guideline development/refinement






Development of (Q)SARs






General workflow in IATA

Multiple strategies
e.g. in house data,
mining of relevant
data bases,
literature search






Framework for how an AOP can be applied to inform and structure IATA





Milestones achieved

Main milestones achieved since the launch of the OECD AOP Development Programme



Search for publications and data
Advanced Search Search Tips

You are here: Home / Papers / OECD Series on Adverse Outcome Pathways

OECD Series on Adverse Outcome Pathways

Email this page
Subscribe to the feed



Hide / Show Abstract

ISSN: 2415-170X (online)
DOI: 10.1787/2415170x



An Adverse Outcome Pathway (AOP) describes a logical sequence of causally linked events at different levels of biological organisation, which follows exposure to a chemical and leads to an adverse health effect in humans or wildlife. AOPs are the central element of a toxicological knowledge framework, promoted by member countries through OECD, built to support chemical risk assessment based on mechanistic reasoning. These AOPs are available in the AOP Wiki, an interactive and virtual encyclopaedia for AOP development. Following their development and review, the endorsed AOPs are published the OECD Series on Adverse Outcome Pathways. As scientific knowledge progresses, the publication of an AOP in this series does not preclude the regular update or new contributions to a given AOP in the AOP Wiki. While the AOP Wiki is a dynamic tool, only impactful changes to the AOP will be reflected in subsequent updates of the published AOP. The number 1 in the OECD Series on Adverse Outcome Pathways is the Users' Handbook, which is a supplement to the Guidance Document for developing and assessing AOPs. This handbook contains an updated template for AOP development and provides focused and practical instructions for both AOP developers and reviewers. For more information, please visit the OECD website on AOPs.

Hide / Show all Abstracts

Mark	Date	Title	Click to Access
------	------	-------	-----------------



Skin sensitisation AOP and alternative method toolbox



In vitro skin absorption (TG 428)

QSARs

In silico toxicokinetic models

TG 442C (DPRA)

QSARs

TG 442D (ARE-Nrf2 Luciferase test method, KeratinoSens™) LuSens

h-CLAT (TG 442E) U-SENS™

Sens-is

IL-8 Luc assay
RhE IL-18

In vitro T cell priming/proliferation


Local Lymph Node Assay

Guinea Pig Maximisation Test

Buehler Test

AOP from *ENV/JM/MONO(2012)10/PART1*


Skin sensitisation: many possibilities of combining information





Takenouchi et al. (2015) J. Appl. Toxicol.: STS & ITS

Score	h-CLAT MIT	DPRA depletion	DEREK
3	≤10 µg/mL	≥42.47%	-
2	>10, ≤150 µg/mL	≥22.62, <42.47%	-
1	>150, ≤5000 µg/mL	≥6.376, <22.62%	Alert
0	not calculated	<6.376%	No alert


Potency: Total battery score	Strong :	7
	Weak :	2-6
	Not classified :	0-1



Hirota et al. (2015) J. Appl. Toxicol.: Artificial Neural Network



Natsch et al. (2015) Toxicological Science Global/domain-based assessment



Jaworska et al. (2015) Arch. Toxicol.: Bayesian Network



Search the ECHA Website

Advanced search >

- About Us
- Regulations
- Addressing Chemicals of Concern
- Information on Chemicals
- Chemicals in our Life
- Support

ECHA > News and Events >



- + About Us
- + Regulations
- + Addressing Chemicals of Concern
- + Information on Chemicals
- + Chemicals in our Life
- + Support

Registrants to use alternative test methods for skin sensitisation

ECHA/NI/16/32

The REACH requirements for skin sensitisation are changing, making non-animal testing the default requirement. Registrants are encouraged to consider their testing strategies now for the 2018 registration deadline.

Helsinki, 5 July 2016 - The amended REACH annexes concerning skin sensitisation are expected to enter into force in autumn 2016. The information needed for the classification or risk assessment of a substance will then be obtained through non-animal methods as a first step. *In vivo* methods can only be used if the *in chemico* or *in vitro* test methods are not adequate for the substance or cannot be used for classification and risk assessment.

With the amended requirements, if a substance is predicted to be a skin sensitiser based on the available data, skin sensitisation potency should also be assessed. There is currently no standardised way to assess potency with the *in vitro* methods and therefore the *in vivo* test may still be necessary.


However, estimating potency is not necessary if an existing *in vivo* study does not allow potency estimation and the study has been performed according to internationally-adopted test methods and good laboratory practice.



AOP-KB



AOP-KB modules



Main Page

Main Page

Contents [hide]

- 1 Announcements
- 2 Welcome to the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki)
 - 2.1 Disclaimer
- 3 How to add a new AOP
 - 3.1 Before You Start
 - 3.2 OECD User Handbook
 - 3.3 Commenting on AOPs
 - 3.4 To create a new AOP
 - 3.5 To edit AOP wiki pages
 - 3.6 To edit other wiki pages (key events, MIE's, etc.)

Announcements

There was a minor software upgrade for the AOP-Wiki on 2/13/2016. A list of the bug fixes and new features is available here:

[Release_Notes#Release_1.5_.281.2F17.2F2016.29](#). If you notice any problems, please email aopwiki@googlegroups.com and/or report here: [Bug Reports](#).

Welcome to the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki)

If you are interested in contributing AOP-related knowledge to the AOP-KB, please follow the instructions laid out at the [OECD Adverse Outcome Pathways, Molecular Screening and Toxicogenomics](#) page. The [Guidance on Developing and Assessing AOPs](#) document is the basis for all work related to contributing and sharing AOP-related knowledge. A [Users' Handbook Supplement](#) to this Guidance has been written to aid systematic development and transparent assessment of Adverse Outcome Pathways (AOPs). The handbook contains a template to guide AOP description and

- Navigation
 - Main page
 - AOP List
 - AOP Table
 - EAGMST Approved AOPs
 - Help
 - FAQ
 - Recent changes
 - Release notes
- Actions
 - Create new AOP
- Feedback


- Tools
 - What links here
 - Related changes
 - Special pages
 - Printable version
 - Permanent link
 - Page information



The Online Encyclopedia of Adverse Outcome Pathways

Effectopedia

Effectopedia is an open-knowledge aggregation and collaboration tool designed to facilitate the interdisciplinary efforts for delineating **adverse outcome pathways (AOPs)** in an encyclopedic manner with greater predictive power. As a response to the growing awareness that a paradigm shift in chemical risk assessment is needed, Effectopedia provides a capability to move beyond the last half-century's phenomenological approach with animal testing to a more mechanistic and hypothesis-driven approach. The 21st-Century shift to more prospective hypothesis generation requires more strategic use of systems biology, QSAR and archived toxicological information in the form of AOPs. Effectopedia is designed as a new technology both to reduce multidisciplinary barriers in the development of AOPs and to integrate AOPs with historical case studies.



Retrieve all Adverse Outcome Pathways

Enter query to retrieve matching AOP titles, or leave blank to display all AOPs

Example: Androgen

START QUERY »

Results

8 page(s) | [next page](#)

AOP Title ^ v	View in native app	AOP Source ^ v
5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase	AOP195	https://aopwiki.org/
5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to decreased shelter seeking and increased predation	AOP98	https://aopwiki.org/

AOP-KB

AOP

- Background
- OECD Guidance
- OECD Handbook

AOP-KB

- AOP-Wiki
- AOP-Xplorer
- Effectopedia
- IEDB

AOP-Lists

AOP-KB Search

Contribute

Resources

Partners

• Enter your search phrase here

Available sorting options:
status, title , creation date, last modification date

Search

200 adverse outcome pathways found from 2

3000 key events found from 2 modules

Sort by

As in the current e.AOP.Portal show a paginated list of AOPs sorted in alphabetic order of the titles form all available data sources (AOP-Wiki and Effectopedia). Allow user to choose different sorting criteria arrange with combo box or list of options: (which can allow users to choose between ascending or descending order)

Sort by: status, **title**▼ , creation date, last modification date

[Aromatase inhibition leading to reproductive dysfunction \(in fish\)](#)


<https://aopkb.org/aopwiki/index.php/Aop:25>

Aromatase, Inhibition; 17beta-estradiol synthesis by ovarian granulosa cells, Reduction; Cumulative fecundity and spawning, Reduction; Plasma 17beta-estradiol concentrations, Reduction; Plasma vitellogenin concentrations, Reduction; Transcription and translation of vitellogenin in liver, Reduction; Vitellogenin uptake into oocytes and oocyte growth/development, Reduction; Population trajectory, Decrease ...

Created on 01.01.2014, Last updated 14.01.2016, Status: EAGMST Approved , Project number, Review Report, i-Library
Source AOP-Wiki



Interlinkages between systems - data exchange





Websites for further information

- OECD public website on Adverse Outcome Pathways:
<http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecular-screening-and-toxicogenomics.htm>
- e.AOP.Portal:
 - Test platform <http://aopkb-pp.oecd.org/>
 - Production platform <http://aopkb.oecd.org/> when the domain name will be transferred
- Wiki platform: <https://aopkb.org/aopwiki>
- Effectopedia: <http://www.effectopedia.org/>




THANK YOU



Types of IATA

Flexible

Judgement-based



Prescriptive

Rule-based



Non-formalised approaches
e.g. grouping and read-across



"Structured approaches"
e.g. Integrated Testing Strategy (ITS)

OECD IATA Case
Studies Project

OECD Project on
defined
approaches



Defined approaches

- A defined approach to testing and assessment consists of a fixed data interpretation procedure (DIP) (e.g. sequential testing strategies, regression models, 2 out of 3 WoE, scoring systems, machine learning approaches, Bayesian networks, etc...) applied to data generated with a defined set of information sources (formalised decision-making approach)
- The result can either be used on its own, or together with other information sources within an IATA